A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C.W., le Roux, Carel W., Violante Ortiz, Rafael, Jensen, Christine Bjørn, Wilding, John P.H.·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1411892

Cited by (1,037)

Items 601–700 of 1,037

  1. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists
    Albert Ko, Yu-Cheng Chang, Furkan Bahar, Tsu Hsien Wang, Nutchapon Xanthavanij, Chun-Chiao Yu, Rebecca Jen-Ling Hsieh, Xin Ya See, Shao‐Wei Lo, Junmin Song et al. · 2025 · Annals of Internal Medicine
  2. GLP-1 as a target for therapeutic intervention
    Surya Panicker Rajeev, John P.H. Wilding · 2016 · Current Opinion in Pharmacology
  3. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
    Gian Paolo Fadini, Mayur Sarangdhar, Angelo Avogaro · 2018 · BMJ Open Diabetes Research & Care
  4. Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review
    Salvatore Carbone, Dave L. Dixon, Leo Francis Buckley, Antonio Abbate · 2018 · Mayo Clinic Proceedings
  5. Precision Medicine in Weight Loss and Healthy Living
    Richard S. Severin, Ahmad Sabbahi, Abeer Mostafa Mahmoud, Ross A Arena, Shane Aaron Phillips · 2019 · Progress in Cardiovascular Diseases
  6. Bariatric-Metabolic Surgery Utilisation in Patients With and Without Diabetes: Data from the IFSO Global Registry 2015–2018
    Richard Welbourn, Marianne Hollyman, Robin Kinsman, John B. Dixon, RICARDO VITOR COHEN, John M. Morton, Amir A. Ghaferi, Kelvin D. Higa, Johan Ottosson, François N. Pattou et al. · 2021 · Obesity Surgery
  7. A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
    Mariana Cornelia Tilinca, Robert Aurelian Tiucă, Alexandru Burlacu, Andreea Varga · 2021 · Medicina
  8. Obesity in the Asia-Pacific Region: Current Perspectives
    David Tak Wai Lui, Junya Ako, Jamshed J Dalal, Alan Yean Yip Fong, Masashi Fujino, Ari Horton, Rungroj Krittayaphong, Wael A. Almahmeed, Anne Thushara Matthias, Adam J. Nelson et al. · 2024 · Journal of Asian Pacific Society of Cardiology
  9. Obesity and diabetes mellitus in the Arab world
    Naweed SyedKhaleel Alzaman, Asem Ali · 2016 · Journal of Taibah University Medical Sciences
  10. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release
    Bruno Halpern, Márcio C. Mancini · 2016 · Expert Opinion on Drug Safety
  11. Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes
    Nicolai J. Wewer Albrechtsen, Reidar Albrechtsen, Lasse Bremholm, Berit Svendsen, Rune E. Kuhre, Steen Seier Poulsen, Charlotte Bayer Christiansen, Elisa P. Jensen, Charlotte Janus, Linda Hilsted et al. · 2016 · Cell Reports
  12. Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series
    Satoshi Ishii, Yoshio Nagai, Yukiyoshi Sada, Hisashi Fukuda, Yuta Nakamura, Ren Matsuba, Tomoko Nakagawa, Hiroyuki Kato, Yasushi Tanaka · 2019 · Journal of Clinical Medicine Research
  13. Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction
    Marco Trevisan, Edouard L. Fu, Karolina Elisabeth Szummer, Anna Norhammar, Pia Lundman, Christoph Wanner, Arvid Sjölander, Tomas Jernberg, Juan Jesús Carrero · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
  14. Advances in Phenotyping Obesity and in Its Dietary and Pharmacological Treatment: A Narrative Review
    Roberta Pujia, Maria Grazia Tarsitano, Franco Arturi, Antonino DE LORENZO, Andrea Lenzi, Arturo Pujia, Tiziana Montalcini · 2022 · Frontiers in Nutrition
  15. Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
    Alfred Sidney Barritt, Emma Marshman, Mazen Noureddin · 2022 · Alimentary Pharmacology & Therapeutics
  16. Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
    Haase, Christiane Lundegaard, Serratore Achenbach, Maria Giovanna, Lucrezi, Gianluca, Jeswani, Nikita, Maurer, Susanne, Egermann, Ulrich · 2021 · Obesity Facts
  17. Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta‐Analysis
    Konwar, Mahanjit, Bose, Debdipta, Jaiswal, Sanjeet Kumar, Maurya, Mitesh kumar, Ravi, Renju · 2022 · International Journal of Clinical Practice
  18. Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions
    Leonardo de Andrade Mesquita, Laura Fink Wayerbacher, Gilberto Schwartsmann, Fernando Gerchman · 2023 · Archives of Endocrinology and Metabolism
  19. Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
    Camille Lupianez‐Merly, Saam Dilmaghani, Kia Vosoughi, Michael Camilleri · 2024 · Alimentary Pharmacology & Therapeutics
  20. Obesity management: sex-specific considerations
    Tobias Kantowski, Clarissa Schulze zur Wiesch, Jens Aberle, Anne Lautenbach · 2024 · Archives of Gynecology and Obstetrics
  21. Obesity and Cancer
    Sherry Shen, Kristy A. Brown, Angela K. Green, Neil M. Iyengar · 2026 · JAMA
  22. The metabolic vascular syndrome - guide to an individualized treatment
    M Hanefeld, Frank Pistrosch, Stefan Richard Bornstein, Andreas L. Birkenfeld · 2016 · Reviews in Endocrine and Metabolic Disorders
  23. Novel Pharmacotherapy Options for NASH
    Vlad Ratziu · 2016 · Digestive Diseases and Sciences
  24. Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis
    Carel Wynand le Roux, Vanita R. Aroda, Joanna Uddén, Ana‐Paula Cancino, Rune Haubo Bojesen Christensen, Xavier Pi-Sunyer · 2017 · Obesity Facts
  25. GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans
    Ruth Hanßen, Alina Chloé Kretschmer, Lionel Rigoux, Kerstin Albus, Sharmili Edwin Thanarajah, Tamara Sitnikow, Corina Melzer, Oliver A. Cornely, Jens C. Brüning, Marc Tittgemeyer · 2021 · Molecular Metabolism
  26. Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss
    Han, Sabrina H, Ockerman, Kyle, Furnas, Heather, Mars, Patricia, Klenke, Audrey, Ching, Jessica, Momeni, Arash, Sorice-Virk, Sarah · 2024 · Aesthetic Surgery Journal
  27. Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review
    Watkins, Jonathan D, Koumanov, Françoise, Gonzalez, Javier T · 2021 · Advances in Nutrition
  28. Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real‐world setting: A 6‐month retrospective study in the United States (SCOPE)
    Ruseva, Aleksandrina, Michalak, Wojciech, Zhao, Zhenxiang, Fabricatore, Anthony, Hartaigh, Bríain Ó., Umashanker, Devika · 2024 · Obesity Science & Practice
  29. Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
    Kolotkin, R. L., Fujioka, K., Wolden, M. L., Brett, J. H., Bjorner, J. B. · 2016 · Clinical Obesity
  30. Glucagon-like peptide-1 receptor agonists and major adverse cardiovascular events in patients with and without diabetes: a meta-analysis of randomized-controlled trials
    Hosseinpour, Alireza, Sood, Aayushi, Kamalpour, Jahangir, Zandi, Ehsan, Pakmehr, SeyedAbbas, Hosseinpour, Hamidreza, Sood, Akshit, Agrawal, Ankit, Gupta, Rahul · 2024 · Clinical Cardiology
  31. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment
    Erik Stenberg, Erik B. Näslund · 2023 · International Journal of Obesity
  32. Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
    Valeria Guglielmi, Silvia Bettini, Paolo Sbraccia, Luca Busetto, Massimo Pellegrini, Volkan Yumuk, Anna Maria Livia Colao, Marwan El Ghoch, Giovanna Muscogiuri · 2023 · Current Obesity Reports
  33. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease
    Jakub Rochoń, Piotr Kalinowski, Ksenia Szymanek-Majchrzak, Michał Grąt · 2024 · World Journal of Gastroenterology
  34. The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
    Pei Zhang, Yu Liu, Yuan Ren, Jie Bai, Guangzhen Zhang, Yuanshan Cui · 2019 · African Health Sciences
  35. Appetite, the enteroendocrine system, gastrointestinal disease and obesity
    Benjamin J. Crooks, Nikoleta S. Stamataki, John T. McLaughlin · 2020 · Proceedings of The Nutrition Society
  36. Albumin-binding domain extends half-life of glucagon-like peptide-1
    Huanbo Tan, Wencheng Su, Wenyu Zhang, Jie Zhang, Michael Sattler, Peijian Zou · 2020 · European Journal of Pharmacology
  37. Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
    Sanjay Kalra, Saptarshi Bhattacharya, Nitin Kapoor · 2021 · Diabetes Therapy
  38. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
    Francisco Westermeier, Enrique Z. Fisman · 2025 · Cardiovascular Diabetology
  39. Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
    Jeon, Eonju, Lee, Ki Young, Kim, Kyoung-Kon · 2023 · Journal of Obesity & Metabolic Syndrome
  40. Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
    Hropot, Tim, Herman, Rok, Janez, Andrej, Lezaic, Luka, Jensterle, Mojca · 2023 · International Journal of Molecular Sciences
  41. Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
    Santini, Sara, Vionnet, Nathalie, Pasquier, Jérôme, Gonzalez‐Rodriguez, Elena, Fraga, Montserrat, Pitteloud, Nelly, Favre, Lucie · 2023 · Obesity
  42. Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials
    Leite, Ana Rita, Angélico‐Gonçalves, António, Vasques‐Nóvoa, Francisco, Borges‐Canha, Marta, Leite‐Moreira, Adelino, Neves, João Sérgio, Ferreira, João Pedro · 2022 · Diabetes, Obesity and Metabolism
  43. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
    Bernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, Peter R Rossing, Thomas Idorn · 2022 · Therapeutic Advances in Endocrinology and Metabolism
  44. Präoperative Evaluation erwachsener Patientinnen und Patienten vor elektiven, nicht herz-thoraxchirurgischen Eingriffen
    Christian Zöllner, Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Andreas B. Böhmer, Götz Geldner, Jörg Karst, Frank Wappler, Bernhard Zwißler, Matthias Pauschinger, U. Obertacke, Tim Oliver Vilz et al. · 2024 · Die Anaesthesiologie
  45. Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
    Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo · 2025 · International Journal of Molecular Sciences
  46. How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis
    Oluwaseun Anyiam, Arash Ardavani, Rushdina Sofia Abdul Rashid, Avinash Panesar, ISKANDAR RAUF IDRIS · 2025 · Obesity Reviews
  47. Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
    Thomas A. Lutz, Elena Osto · 2016 · Current Opinion in Lipidology
  48. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
    Haitham M. Ahmed, Haitham Khraishah, Leslie Cho · 2017 · European Heart Journal
  49. Incremental cost‐effectiveness of evidence‐based non‐surgical weight loss strategies
    Eric Andrew Finkelstein, Naina R. Verghese · 2019 · Clinical Obesity
  50. Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea–hypnoea index (AHI)
    Victoria S. Sprung, Graham John Kemp, John P.H. Wilding, Valerie L. Adams, Kieran Murphy, Malcolm I. Burgess, Stephen Emegbo, Matthew Thomas, Alexander J Needham, Andrew Weimken et al. · 2020 · BMJ Open
  51. Obesity therapy
    Stephan C. Bischoff, Anna Schweinlin · 2020 · Clinical Nutrition ESPEN
  52. Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
    Moon, Shinje, Lee, Jibeom, Chung, Hye Soo, Kim, Yoon Jung, Yu, Jae Myung, Yu, Sung Hoon, Oh, Chang-Myung · 2021 · Endocrinology and Metabolism
  53. Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
    Nikolic, Dragana, Patti, Angelo M., Giglio, Rosaria V., Chianetta, Roberta, Castellino, Giuseppa, Magán-Fernández, Antonio, Citarrella, Roberto, Papanas, Nikolaos, Janez, Andrej, Stoian, Anca Pantea et al. · 2022 · Diabetes Therapy
  54. Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future
    Łukasz Szczerbiński, José C. Florez · 2023 · The Lancet Diabetes & Endocrinology
  55. Impact of GLP-1 Agonists on Male Reproductive Health—A Narrative Review
    Alexandra Aponte Varnum, Edoardo Pozzi, Nicholas A. Deebel, Aymara Evans, Nathalie Eid, Hossein Sadeghi‐Nejad, Ranjith Ramasamy · 2023 · Medicina
  56. Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss
    Jesse R. Richards, Sahib S. Khalsa · 2024 · Obesity Reviews
  57. Obesity and Weight Loss Strategies for Patients With Heart Failure
    Amanda Ruth Vest, Philip R. Schauer, Jo E. Rodgers, Emily Sanderson, Courtney LaChute, Jessica Seltz, Carl J. Lavie, Stacy A. Mandras, W.H. Wilson Tang, Adrian daSilva‐deAbreu · 2024 · JACC Heart Failure
  58. Gut microbiota: a target for intervention in obesity
    Kanika Sehgal, Sahil Khanna · 2021 · Expert Review of Gastroenterology & Hepatology
  59. Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
    Kannt, Aimo, Madsen, Andreas Nygaard, Kammermeier, Claire, Elvert, Ralf, Klöckener, Tim, Bossart, Martin, Haack, Torsten, Evers, Andreas, Lorenz, Katrin, Hennerici, Wolfgang et al. · 2020 · Diabetes, Obesity and Metabolism
  60. Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective
    Ainhoa Gómez-Lumbreras, Malinda Sunnita Tan, Lorenzo Villa Zapata, Sabrina Ilham, Jacob Craig Earl, Daniel C. Malone · 2023 · Nutrition Metabolism and Cardiovascular Diseases
  61. Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study
    Kang Chen, Li Chen, Zhongyan Shan, Guixia Wang, Shen Qu, Guijun Qin, Xuefeng Yu, Weiquan Xin, Tsung‐han Hsieh, Yiming Mu · 2023 · Diabetes Obesity and Metabolism
  62. The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis
    Michel Garcia Maciel, Bruna Teles Soares Beserra, Fernanda Cerqueira Barroso Oliveira, Carolina Martins Ribeiro, Michella Soares Coêlho, Francisco de Assis Rocha Neves, Angélica Amorim Amato · 2018 · Diabetes Research and Clinical Practice
  63. Gender‐related issues in the pharmacology of new anti‐obesity drugs
    Mauro Cataldi, Giovanna Muscogiuri, Silvia Savastano, Luigi Barrea, Bruna Guida, Maurizio Taglialatela, Annamaria Anita Livia Colao · 2018 · Obesity Reviews
  64. Is reducing appetite beneficial for body weight management in the context of overweight and obesity? A systematic review and meta‐analysis from clinical trials assessing body weight management after exposure to satiety enhancing and/or hunger reducing products
    Thea Toft Hansen, Sarah Vold Andersen, Arne Vernon Astrup, John Edward Blundell, Anders Mikael Sjödin · 2019 · Obesity Reviews
  65. Documento de consenso de la Sociedad Española de Obesidad (SEEDO) y de la Sociedad Española de Médicos de Atención Primaria (SEMERGEN) sobre la continuidad asistencial en obesidad entre Atención Primaria y Unidades Especializadas Hospitalarias 2019
    Assumpta Caixàs, Mercè Villaró, Carmen Arraiza Irigoyen, Juan-Carlos Montalvá, Albert Lecube, José-Manuel Fernández-García, Rosario Corio, Diego Bellido, J.L. Llisterri, Francisco José Tinahones · 2020 · Medicina Clínica
  66. Modulatory role of gut microbiota in cholesterol and glucose metabolism: Potential implications for atherosclerotic cardiovascular disease
    Johann Roessler, David M. Leistner, Ulf Landmesser, Arash Haghikia · 2022 · Atherosclerosis
  67. Regulation of adipogenesis by exosomal milk miRNA
    Manal Ahmad Abbas, Noor Nadhim Al-Saigh, Fadi G. Saqallah · 2023 · Reviews in Endocrine and Metabolic Disorders
  68. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis
    Stefanou, Maria-Ioanna, Palaiodimou, Lina, Theodorou, Aikaterini, Safouris, Apostolos, Fischer, Urs, Kelly, Peter J., Dawson, Jesse, Katan, Mira, Katsanos, Aristeidis H., Lambadiari, Vaia et al. · 2024 · Therapeutic Advances in Neurological Disorders
  69. GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
    Arredouani, Abdelilah · 2025 · Pharmacology & Therapeutics
  70. Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial
    Qing Wen, Song Fang, Yanjing Liang, Yuting Tian, Yiding Chen, Jun Yuan, Chen Qiu · 2023 · Frontiers in Endocrinology
  71. Long‐acting glucagon‐like peptide‐1 receptor agonists have direct access to and effects on pro‐opiomelanocortin/cocaine‐ and amphetamine‐stimulated transcript neurons in the mouse hypothalamus
    Lotte Bjerre Knudsen, Anna Secher, Jacob Hecksher‐Sørensen, Charles Pyke · 2016 · Journal of Diabetes Investigation
  72. Vascular risk in obesity: Facts, misconceptions and the unknown
    Rhodri King, Ramzi Ajjan · 2016 · Diabetes and Vascular Disease Research
  73. Transient receptor potential (TRP) channels: a metabolic TR(i)P to obesity prevention and therapy
    Mahendra Bishnoi, Pragyanshu Khare, Lindsay Brown, Sunil K. Panchal · 2018 · Obesity Reviews
  74. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
    Rasmus Michael Sandsdal, Christian Rimer Juhl, Signe S. Torekov · 2019 · Drug Safety
  75. Harnessing cyclotides to design and develop novel peptide GPCR ligands
    Edin Muratspahić, Johannes Koehbach, Christian W. Gruber, David J. Craik · 2020 · RSC Chemical Biology
  76. Obesity and GLP-1
    Alejandra Pérez-Montes de, Sílvia Pellitero, Manel Puig‐Domingo · 2021 · Minerva Endocrinology
  77. Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis
    Wineke Bakker, Mónica Imbernón, Casper Gravesen Salinas, Daniela Herrera Moro Chao, Rim Hassouna, Chloe Morel, Claire Martin, Caroline Leger, R Denis, Julien Castel et al. · 2022 · Cell Reports
  78. Bariatric surgery – time to replace with GLP-1?
    Dominic‐Luc Webb, Niclas Abrahamsson, Magnus Sundbom, Per M. Hellström · 2017 · Scandinavian Journal of Gastroenterology
  79. Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs
    Barbara Capuani, Francesca Pacifici, David Della‐Morte, Davide Lauro · 2018 · Frontiers in Endocrinology
  80. Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis
    Dutta, Deep, Nagendra, Lakshmi, Anne, Beatrice, Kumar, Manoj, Sharma, Meha, Kamrul‐Hasan, A. B. M. · 2024 · Obesity Science & Practice
  81. Factors associated with successful weight loss after liraglutide treatment for obesity
    Wassel Sannaa, Saam Dilmaghani, Joelle BouSaba, Daniel Barry Maselli, Jessica Atieh, Deborah J. Eckert, Ann L. Taylor, William Scott Harmsen, Andres J Acosta, Michael Camilleri · 2022 · Diabetes Obesity and Metabolism
  82. Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
    Özge Telci Çaklılı, Mustafa Cesur, Dimitri P. Mikhailidis, Manfredi Rizzo · 2023 · Diabetes Metabolic Syndrome and Obesity
  83. Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions
    Arne Vernon Astrup · 2024 · European Journal of Clinical Nutrition
  84. Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
    Claire Parker, Craig Slattery, Donal J. Brennan, Carel Wynand le Roux · 2025 · Diabetes Obesity and Metabolism
  85. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications
    Mariana Michelle Ramírez-Mejía, Guadalupe Ponciano‐Rodríguez, Mohammed Eslam, Nahúm Méndez-Sánchez · 2025 · Therapeutic Advances in Endocrinology and Metabolism
  86. Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
    Susan Leanne Samson, Alan J. Garber · 2016 · Best Practice & Research Clinical Endocrinology & Metabolism
  87. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists
    Luigi Barrea, Gabriella Pugliese, Giovanna Muscogiuri, Daniela Laudisio, Annamaria Anita Livia Colao, Silvia Savastano · 2020 · Minerva Endocrinology
  88. Drugs for Treating Obesity
    Donna H. Ryan · 2021 · Handbook of experimental pharmacology
  89. The Fatty Kidney and Beyond: A Silent Epidemic
    Nang San Hti Lar Seng, Petras Jairam Das Lohana, Shruti Chandra, Belinda Jim · 2023 · The American Journal of Medicine
  90. Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery
    Michail Kokkorakis, Angeliki Katsarou, Niki Katsiki, Christos Socrates Mantzoros · 2023 · Metabolism
  91. New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
    Ryan, Donna H. · 2025 · Reviews in Endocrine and Metabolic Disorders
  92. Cracking the combination: Gut hormones for the treatment of obesity and diabetes
    Alexiadou, Kleopatra, Anyiam, Oluwaseun, Tan, Tricia · 2019 · Journal of Neuroendocrinology
  93. Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved
    Trenson, Liesbet, Trenson, Sander, van Nes, Falco, Moyson, Carolien, Lannoo, Matthias, Deleus, Ellen, Meulemans, Ann, Matthys, Christophe, Mertens, Ann, Van der Schueren, Bart et al. · 2022 · Obesity Facts
  94. Fatty Acids Increase GDF15 and Reduce Food Intake Through a GFRAL Signaling Axis
    Dongdong Wang, Maria Joy Therese Jabile, Junfeng Lu, Logan K. Townsend, Celina M Valvano, Jaya Gautam, Battsetseg Batchuluun, Evangelia Evelyn Tsakiridis, James Lally, Gregory R. Steinberg · 2023 · Diabetes
  95. Obesity and cardiovascular disease: Risk assessment, physical activity, and management of complications
    Francesco Perone, Luigi Spadafora, Alessandra Pratesi, Giulia Nicolaio, Barbara Pala, Giulia Franco, Matteo Ruzzolini, Marco Ambrosetti · 2024 · International Journal of Cardiology Cardiovascular Risk and Prevention
  96. Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis
    Ruifeng Yang, Lindong Zhang, Jiangfan Guo, Ning Wang, Qiue Zhang, Zhiwei Qi, Lili Wu, Lingling Qin, Tonghua Liu · 2025 · Journal of Translational Medicine
  97. MetALD : New Perspectives on an Old Overlooked Disease
    Gustavo Ayares, Luis Antonio Díaz, Francisco Javier Idalsoaga, Naim Alkhouri, Mazen Noureddin, Ramon A. Bataller, Rohit Seth Loomba, Juan Pablo Arab, Marco A. Arrese · 2025 · Liver International
  98. Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study
    Hans Hauner, Ljiljana Hastreiter, Dieter Werdier, Annette Chen-Stute, Jürgen Scholze, Matthias Blüher · 2017 · Obesity Facts
  99. Liraglutide in Weight Management
    Xavier Pi-Sunyer · 2015 · New England Journal of Medicine
  100. Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus
    Bae, Jae Hyun, Choi, Hyung Jin, Cho, Kang Ik Kevin, Kim, Lee Kyung, Kwon, Jun Soo, Cho, Young Min · 2020 · Diabetes & Metabolism Journal